innoscripta Puts the Onus on Clients as Tax Probe Clouds Its Market Debut Year

innoscripta says clients or their tax advisers formally submit research-grant applications, as a criminal tax probe weighs on its shares.

innoscripta is drawing a clear boundary around who bears responsibility for the research-grant applications now at the center of a criminal tax investigation, arguing that its own role ends well before the paperwork reaches the authorities.

In a statement, the company laid out how the process works: innoscripta handles the preparatory work, while the final review of all data and the actual submission of applications rest formally with clients or their tax advisers. The clarification comes as the group works to map out its internal procedures following enforcement action by prosecutors.

The probe itself concerns suspected aiding and abetting in the obtaining of unjustified tax benefits tied to research grants for clients. According to innoscripta's preliminary assessment, the allegations point to possible misconduct by individual former employees in connection with specific client mandates. The company said any financial or other consequences from the ongoing proceedings cannot yet be fully assessed.

Operations Said to Be Untouched

Management stressed that day-to-day business continues without restriction, and that, based on current knowledge, no transactions in the current fiscal year are affected by the authorities' investigation. The company also pledged full cooperation with the relevant agencies to clear up the matter.

Authorities searched innoscripta's business premises and those of other group companies roughly three weeks ago, when news of the investigation first surfaced.

To shore up confidence in the capital markets, innoscripta has invited shareholders to a personal product presentation in Tutzing. Dates for the event are to be announced at short notice.

A Bruising Stretch for the Share Price

The uncertainty has left deep marks on the stock. German trading on Tuesday showed the shares at EUR 45.05, down 2.1%, after closing at EUR 46.00 on Monday. Media reports noted a temporary countermove at the start of the week following a slump the week before, while investors also reported that the stock was at times difficult to trade through certain brokers.

Measured from the beginning of the year, the decline stands at 50%, leaving the company with a market capitalization of EUR 885.00 million.

For investors, the question is whether the current valuation already reflects the full extent of the risk. The market has absorbed the initial shock but is now pricing in persistent uncertainty, forcing a weighing of the price trajectory against the open questions of the legal reckoning. Any reliable judgment depends on how sturdy the company's disclosures prove to be.

Where the Case Could Turn

Much hinges on the character of the misconduct. Should innoscripta's account hold — that the described events trace back to individual employees — the core of the organization would remain intact. If the allegations cannot be confined to specific persons, however, the entire approach to filing grant applications would be called into question. Legal compliance is the most valuable asset in a business built on supporting clients' research-grant claims, and doubts about the integrity of those processes cut sharply into the company's reputation.

The company's assurance that no current-year transactions are affected serves as the key support for ongoing operations. If the authorities confirm that scope, potential fallout stays contained; if the investigation widens across time, fundamental revisions loom.

The Case for Stabilization

The optimistic scenario rests on business continuing as usual, with existing client relationships served without interruption. Add to that the promised cooperation with investigators: a swift, transparent working-through of the allegations could gradually bring institutional investors back. A clean cut separating individual wrongdoing from the quality of the service offering is the goal.

Technological progress is another pillar. The announced shareholder product presentation, whose dates will be communicated shortly, gives management a stage to show viable solutions and put innovative strength back in the spotlight. A calmer legal front would give the shares room to recover.

What Could Go Wrong

Tangible risks remain that could extend the slide. The company itself noted that financial or other effects cannot yet be conclusively assessed — a formulation that signals considerable lingering uncertainty to the market. Fines, financial claims or damages would hit the balance sheet directly. The heavier burden may be reputational: companies could hesitate to file applications through a service provider whose methods are under tax-authority scrutiny.

Investigations of this kind also tie up management capacity for months. Instead of pursuing expansion, the leadership must devote itself to legal defense and internal review. Should control mechanisms prove to have failed, costly requirements and structural overhauls could follow — an environment in which selling pressure on the exchanges would stay elevated.

Two factors will set the course from here. As long as the assurance holds that the current fiscal year remains unaffected and operations run smoothly, the stock can find a floor, giving bold investors arguments for stabilization. Should new findings from the authorities overturn that assumption, another wave of selling threatens, with any broadening of the probe into further areas damaging confidence anew. The next concrete anchor is the shareholder product presentation, where management must prove that its operating direction is sound and clients remain the priority. Until firm dates for that event are set and the investigation comes into focus, the situation stays demanding for investors.